Ethical Issues in the Treatment of Late-Stage Alzheimer's Disease
Andrew D Watt, Nicole L Jenkins, Gawain McColl, Steven Collins, Patricia M Desmond
JOURNAL OF ALZHEIMERS DISEASE | IOS PRESS | Published : 2019
There is hope that the continuing efforts of researchers will yield a disease-modifying drug for Alzheimer's disease. Such a drug is likely to be capable of halting, or significantly slowing, the underlying pathological processes driving cognitive decline; however, it is unlikely to be capable of restoring brain function already lost through the pathological process. A therapy capable of halting Alzheimer's disease, while not providing restoration of function, may prompt serious ethical questions. For example, is there a stage in the disease process when it becomes too late for therapeutic intervention to commence? And who bears the responsibility of making such a decision? Conversations reg..View full abstract
Related Projects (1)
Awarded by NHMRC Practitioner Fellowship
We acknowledge the Victorian Government's Operational Infrastructure Support Program. SC is supported in part by a NHMRC Practitioner Fellowship (#APP1105784).